The microbial contract biomanufacturing market is projected grow at an annualized rate of 8.7%, till

Roots Analysis has done a detailed study on “Microbial Contract Biomanufacturing Market, 2020-2030” covering key aspects of the industry and identifying potential future growth opportunities.

To order this 320+ page report, which features 150+ figures and 150+ tables, please visit this –

Key Market Insights
 Over 115 companies, across the world, claim to offer a variety of product development, manufacturing and support services, for various types of biologics that are manufactured / expressed in microbial systems
 Majority of the players have the necessary infrastructure / capability to produce different biologics, primarily proteins, at all scales using bacterial / yeast expression vectors
 The market features the presence of several well-established players across the globe; the US, the UK and Germany emerged as current hubs for production of biologics using microbial strains
 Several service providers, involved in this domain, are steadily expanding their capabilities in order to enhance their respective service portfolio and maintain a competitive edge in the industry
 The growth trend of outsourcing microbial manufacturing operations is evident from the rise in recent partnership activity, as well as expansion initiatives undertaken by CMOs to meet the growing demand for novel biologics
 Big pharma players have also made significant investments in this domain through establishment of new facilities, entering into strategic collaborations and undertaking financial investments
 Future growth of the market is likely to be driven by increased adoption of novel biologics that are produced via microbial systems;

Contact Details

Gaurav Chaudhary

+1 (415) 800 3415

Leave a Reply

Your email address will not be published. Required fields are marked *